pharmaceutical industry; contract manufacturing industry
Founded
1984 (1984) in Winnipeg, Manitoba, Canada
Defunct
2014 (2014)
Fate
Acquired by Emergent BioSolutions
Divisions
Cangene bioPharma (CMO)
Cangene Corporation was a biopharmaceutical company based in Winnipeg, Manitoba, Canada. It was founded in 1984 and specialized in hyperimmunes, contract manufacturing, biopharmaceuticals and biodefense. Cangene was 61% owned by Canadian pharmaceutical giant Apotex and was publicly listed on the TSX under the symbol CNJ.
Cangene Corporation was a biopharmaceutical company based in Winnipeg, Manitoba, Canada. It was founded in 1984 and specialized in hyperimmunes, contract...
(trade name BAT), made by Emergent BioSolutions Canada Inc. (formerly Cangene Corporation) – is a licensed, commercially available botulism anti-toxin...
Apotex owned 61% of Cangene Corp., a Winnipeg-based biopharmaceutical company, according to Cangene's 2007 annual report. Cangene's business focuses are...
is a research & laboratory and cGMP-production facility. Developed by Cangene in 1982 with additions in 2003 and 2006, it was purchased in 2014 by Emergent...
bacteria. BARDA also supported the development of the antitoxins Anthrasil of Cangene (March 2015 FDA approval) and Anthim of Elusys Therapeutics (March 2016...
that lasted up to 8 hours. Episil oral liquid is marketed in the US by Cangene. In a 2012 randomized controlled pilot study involving pediatric patients...
inoculation. Cangene (a subsidiary of Emergent BioSolutions) brand-name VIGIV is also known by an alternate name: C-VIG; CNJ 016; NP 016 – Cangene; VIG; VIGIV...
the year 2020. The company purchased Winnipeg, Manitoba's Cangene Corporation in 2013. Cangene's leading product is WinRho, which treats the blood disease...
plasma. The others are Canadian Blood Services (CBS), Hema-Quebec and Cangene, now owned by ProMetic Life Sciences Inc. Canadian Plasma Resources is...
pharmaceuticals and biotechnology, companies such as Apotex and Winnipeg based Cangene Corp., have become world leaders in the development of generic drugs and...
102 doses of Raxibacumab. 10,000 doses of anthrax immune globulin from Cangene, which also treats anthrax. By 2010, the supply was down to 7,327 doses...
in combination with antibiotics to treat anthrax. It was developed by Cangene and purchased in 2011 by the Biomedical Advanced Research and Development...
fractionation to North America in 1972. He was one of the main contributors to Cangene Corporation's development and licensing in Canada in 1980 of WinRho, in...
Fellowship awarded by the Canadian Institutes of Health Research 2006, Cangene Gold Award 2006-2008, JMH Junior Research Fellowship awarded by Linacre...